Jul. 2 at 10:12 PM
One of the strongest sectors outside of AI right now is Biotech.
Neurology
$DFTX Definium Therapeutics
$CMPS COMPASS Pathways
$DNLI Denali Therapeutics
$XENE Xenon Pharmaceuticals
$NBIX Neurocrine Biosciences
The 70% correction trap is driving smart money into neuro-therapeutic CNS alpha pipelines. Elite institutions deploy tactical limit entries atop long-term FIB floors, lock-floating neurological monopolies. Disrupter DFTX accelerates right-side PEG defense, surging on its upsized
$805M public offering and pivotal Phase 3 depression data catalysts. It pairs with psychedelic pioneer CMPS at key FIB accumulation zones, while blood-brain-barrier innovator DNLI scales following fresh Russell growth index flows. Flanking them are commercial powerhouse BIIB and pipeline leader XENE hardening their valuation ceilings. Technical compression means nothing without clinical milestones. Facing this neuro-rotation, are you buying the FIB support floors on DFTX and CMPS or resting in defensive cash?
